Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2015 Jan;50(1):139-41. doi: 10.1038/bmt.2014.210. Epub 2014 Sep 29.

Authors

A Salhotra¹, N Tsai², S H Thomas¹, T Paris², P Parker¹, S J Forman¹, R Nakamura¹

Affiliations

¹ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
² Department of Biostatistics, City of Hope, Duarte, CA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adolescent
Adult
Allografts
Chronic Disease
Female
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Protein Kinase Inhibitors / administration & dosage*
Retrospective Studies
Scleroderma, Diffuse / drug therapy*
Scleroderma, Diffuse / etiology

Substances

Protein Kinase Inhibitors

Grants and funding